ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.5726A>G (p.Asp1909Gly) (rs80358798)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000212243 SCV000210366 uncertain significance not provided 2016-01-13 criteria provided, single submitter clinical testing This variant is denoted BRCA2 c.5726A>G at the cDNA level, p.Asp1909Gly (D1909G) at the protein level, and results in the change of an Aspartic Acid to a Glycine (GAT>GGT). Using alternate nomenclature, this variant would be defined as 5954A>G. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA2 Asp1909Gly was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Aspartic Acid and Glycine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. BRCA2 Asp1909Gly occurs at a position that is not conserved and is in the RAD51-binding BRC repeat region in the linker between repeat 6 and 7 (Uniprot). In silico analyses predict that this variant is unlikely to alter protein structure or function; however, multiple splicing models predict that this variant may create a novel cryptic splice site upstream of a strong natural splice donor site and may lead to abnormal splicing. However, in the absence of RNA or functional studies, the actual effect of this variant is unknown. Based on currently available information, it is unclear whether BRCA2 Asp1909Gly is pathogenic or benign. We consider it to be a variant of uncertain significance.
Ambry Genetics RCV000213615 SCV000276237 uncertain significance Hereditary cancer-predisposing syndrome 2015-06-15 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence,In silico models in agreement (benign)
Breast Cancer Information Core (BIC) (BRCA2) RCV000113471 SCV000146680 uncertain significance Breast-ovarian cancer, familial 2 2003-12-23 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.